Compare Cigna Corp (CI) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs Nuscale Power Corporation — how do they compare? Cigna Corp trades at $272.72 (market cap $73.56B), while Nuscale Power Corporation trades at $9.67 (market cap $3.77B). The key difference: Cigna Corp is far larger — about 19.5× Nuscale Power Corporation's market cap, and Cigna Corp pays a 2.24% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.
| CI | SMR | |
|---|---|---|
Market Cap | $73.56B | $3.77B |
Sector | Health | Utilities |
52-Week High | $311.00 | $53.43 |
52-Week Low | $244.41 | $7.59 |
Enterprise Value | $98.27B | $2.70B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $282.49, up 2.63% with strong earnings beats in recent quarters. The stock shows bearish technical signals but benefits from low valuation ratios like a P/E of 11.68 and P/S of 0.27. Recent Q2 2026 results exceeded expectations, with EPS of $7.78 beating estimates, and the company raised its full-year guidance to at least $30.45 adjusted EPS, reflecting robust growth in health services and insurance segments.
The outlook is positive due to consistent earnings outperformance and raised guidance, though technical weakness and competitive pressures pose risks. Analyst consensus is strongly bullish with a $338.90 price target, indicating ~20% upside potential from current levels, supported by dividend payments and institutional accumulation.
NuScale Power (SMR) trades at $9.83, up 3.69% with a bullish technical signal. The company reported Q2 2026 earnings that met estimates but revenues plunged 98.8% as RoPower work wound down. Despite negative profit margins and cash burn, NuScale maintains $1.9 billion liquidity and is advancing commercialization of its NRC-approved small modular reactor technology amid growing AI power demand.
The outlook hinges on successful commercial deployment of SMR technology, with potential for significant upside if large-scale projects materialize. Key risks include execution challenges, revenue volatility, and intense competition in the nuclear energy sector. Analyst consensus suggests 8% upside to the $10.63 price target, but investors should weigh the high-risk, high-reward nature of this pre-revenue growth story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
